|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
US8293685B2
(en)
|
2007-07-26 |
2012-10-23 |
The Regents Of The University Of California |
Methods for enhancing bacterial cell display of proteins and peptides
|
|
EP2190861A4
(en)
*
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
EP3543256A1
(en)
*
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
JP5906090B2
(ja)
|
2009-02-17 |
2016-04-20 |
コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated |
癌の診断のための方法およびキットならびに治療価の推定
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
ES2699965T3
(es)
|
2011-03-10 |
2019-02-13 |
Provectus Pharmatech Inc |
Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
HUE048876T2
(hu)
|
2011-05-09 |
2020-08-28 |
Mayo Found Medical Education & Res |
Rákos megbetegedések kezelése
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
|
EP4624490A3
(en)
|
2012-02-09 |
2025-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
CA2865158C
(en)
|
2012-02-24 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
|
WO2013192546A1
(en)
*
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
SG11201408554QA
(en)
*
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
EP2882844B1
(en)
|
2012-08-10 |
2018-10-03 |
Cytomx Therapeutics Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
|
RU2666990C2
(ru)
|
2012-08-13 |
2018-09-13 |
Дженентек, Инк. |
Антитела к jagged и способы их применения
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
|
JP6605957B2
(ja)
|
2013-01-04 |
2019-11-13 |
シトムクス セラピューティクス,インコーポレイティド |
生体系におけるプロテアーゼ活性を検出するための組成物及び方法
|
|
RU2519546C1
(ru)
*
|
2013-01-16 |
2014-06-10 |
Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") |
КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
|
|
EP2970468B1
(en)
|
2013-03-13 |
2021-07-07 |
Novartis AG |
Notch2 binding molecules for treating respiratory diseases
|
|
EP2970498A4
(en)
*
|
2013-03-15 |
2016-11-23 |
Bayer Healthcare Llc |
PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
SG11201509595PA
(en)
*
|
2013-05-28 |
2015-12-30 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
JP6693872B2
(ja)
*
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス,インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
WO2015023927A2
(en)
*
|
2013-08-16 |
2015-02-19 |
University Of Rochester |
Composition and method for detection of nanomaterials
|
|
KR20250051130A
(ko)
*
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
EP3092256B1
(en)
|
2014-01-10 |
2022-05-18 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
|
EP3628328B1
(en)
*
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
ES2959480T3
(es)
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
SI3105253T1
(sl)
|
2014-02-12 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Protitelesa anti-Jagged1 in načini njihove uporabe
|
|
US20160230202A1
(en)
*
|
2014-03-11 |
2016-08-11 |
Eric William Olle |
Process for Generating Synthetic Engineered Recombinant Proteins for Vaccination, Diagnosis and Treatment of Disease
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
EP3154586B1
(en)
|
2014-06-13 |
2020-05-27 |
Mayo Foundation for Medical Education and Research |
Treating lymphomas
|
|
US10213513B2
(en)
|
2014-06-16 |
2019-02-26 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
DK4001311T3
(da)
|
2014-07-09 |
2026-02-02 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN107073132B
(zh)
|
2014-10-06 |
2021-08-27 |
梅约医学教育与研究基金会 |
载体-抗体组合物及其制备和使用方法
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
AU2016215604B2
(en)
|
2015-02-02 |
2020-08-13 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
MA42971A
(fr)
*
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
BR112017023872A2
(pt)
*
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體-抗體組合物及其製造及使用方法
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US10758886B2
(en)
*
|
2015-09-14 |
2020-09-01 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Conditioned surfaces for in situ molecular array synthesis
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
MA43134A
(fr)
|
2015-10-30 |
2018-09-05 |
Aleta Biotherapeutics Inc |
Compositions et méthodes de transduction tumorale
|
|
CA3003399A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
|
CA3005070A1
(en)
|
2015-11-11 |
2017-05-18 |
Serimmune Inc. |
Methods and compositions for assessing antibody specificities
|
|
HUE054131T2
(hu)
|
2015-11-19 |
2021-08-30 |
Revitope Ltd |
Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
|
|
EP3389720A1
(en)
|
2015-12-18 |
2018-10-24 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
CN105601751B
(zh)
*
|
2016-02-01 |
2019-06-07 |
中国人民解放军第三军医大学 |
一种重组蛋白Vo及其制备方法和应用
|
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
CN109068621B
(zh)
*
|
2016-02-29 |
2021-07-20 |
再生元制药公司 |
具有人源化的tmprss基因的啮齿类动物
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
EP3432928A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
|
|
WO2017165440A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2017205560A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Albert Einstein College Of Medicine, Inc. |
Methods for treating cancer by targeting vcam1 and maea
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
WO2018022957A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Tarveda Therapeutics, Inc. |
T cell binding conjugates and methods of use
|
|
CN109890419A
(zh)
|
2016-09-01 |
2019-06-14 |
梅约医学教育与研究基金会 |
用于治疗癌症的载体-pd-l1结合剂组合物
|
|
CN109843336A
(zh)
|
2016-09-01 |
2019-06-04 |
梅约医学教育与研究基金会 |
用于靶向t细胞癌症的方法和组合物
|
|
CN109843924A
(zh)
|
2016-09-06 |
2019-06-04 |
梅约医学教育与研究基金会 |
治疗表达pd-l1的癌症的方法
|
|
AU2017324947A1
(en)
|
2016-09-06 |
2019-03-28 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
CA3037767A1
(en)
|
2016-09-28 |
2018-04-05 |
Georgia Tech Research Corporation |
Methods and compositions for noninvasive detection of organ transplant rejection
|
|
CN110072890B
(zh)
*
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
|
|
CA3041279A1
(en)
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
AU2017364818C1
(en)
*
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
IL307242B1
(en)
|
2016-12-07 |
2026-07-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
EP3551667A4
(en)
|
2016-12-09 |
2020-06-17 |
Seattle Genetics, Inc. |
BIVALENT ANTIBODIES MASKED BY COILS
|
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
|
CN110636856A
(zh)
*
|
2016-12-29 |
2019-12-31 |
财团法人生物技术开发中心 |
Klk6-介导的cns-特异性抗体前药激活
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP3585817A4
(en)
*
|
2017-02-22 |
2020-12-02 |
Aleta Biotherapeutics Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
EP3609915A1
(en)
*
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antibodies having conditional affinity and methods of use thereof
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
WO2018213335A1
(en)
*
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
|
IL270743B2
(en)
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
US10716858B2
(en)
|
2017-06-30 |
2020-07-21 |
Massachusetts Institute Of Technology |
Branched multi-functional macromonomers and uses thereof
|
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
KR102003594B1
(ko)
*
|
2017-08-08 |
2019-07-24 |
숙명여자대학교산학협력단 |
염증 반응 매개 신혈관생성 질환 진단용 조성물
|
|
WO2019036433A2
(en)
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
CN111212853A
(zh)
|
2017-08-30 |
2020-05-29 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
|
CN111356700A
(zh)
*
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
CN111315773A
(zh)
*
|
2017-09-08 |
2020-06-19 |
马弗里克治疗公司 |
含有Fc区的条件性活化的结合部分
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
PE20210125A1
(es)
|
2017-10-14 |
2021-01-19 |
Abbvie Inc |
Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
AR113862A1
(es)
*
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
WO2019118918A1
(en)
|
2017-12-15 |
2019-06-20 |
Aleta Biotherapeutics Inc. |
Cd19 variants
|
|
CA3086045A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
|
KR20260039804A
(ko)
|
2017-12-21 |
2026-03-20 |
아뮤닉스 파마슈티컬스, 인크. |
유리 세그먼트 및 이것을 포함하는 결합 조성물
|
|
WO2019148444A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
|
CN112005304A
(zh)
|
2018-03-20 |
2020-11-27 |
西托姆克斯治疗公司 |
用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
US20210324088A1
(en)
|
2018-05-02 |
2021-10-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3099419A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
MX2020012217A
(es)
*
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
EP3807312A4
(en)
|
2018-05-30 |
2022-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT
|
|
JP7428661B2
(ja)
*
|
2018-05-30 |
2024-02-06 |
中外製薬株式会社 |
Il-1r1結合ドメインおよび運搬部分を含むポリペプチド
|
|
EP3816182A4
(en)
|
2018-05-30 |
2022-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
|
|
US10640562B2
(en)
*
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
SG11202013248YA
(en)
|
2018-07-31 |
2021-02-25 |
Amgen Inc |
Pharmaceutical formulations of masked antibodies
|
|
MX2021001431A
(es)
|
2018-08-10 |
2021-05-12 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
|
|
US10988491B2
(en)
|
2018-08-17 |
2021-04-27 |
Massachusetts Institute Of Technology |
Degradable polymers of a cyclic silyl ether and uses thereof
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Dll3シングルドメイン抗体およびその治療用組成物
|
|
AU2019356573B2
(en)
|
2018-10-11 |
2025-12-18 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
BR112021008526A2
(pt)
|
2018-11-02 |
2021-08-10 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
JP2022512124A
(ja)
*
|
2018-12-06 |
2022-02-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
|
|
WO2020123980A1
(en)
*
|
2018-12-14 |
2020-06-18 |
Proviva Therapeutics (Hong Kong) Limited |
Il-15 compositions and methods of use thereof
|
|
BR112021012631A2
(pt)
*
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
MA55316A
(fr)
|
2019-03-13 |
2022-01-19 |
Merck Sharp & Dohme |
Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
|
|
AU2020240310A1
(en)
|
2019-03-21 |
2021-10-07 |
Immunogen, Inc. |
Methods of preparing cell-binding agent-drug conjugates
|
|
CA3136602A1
(en)
|
2019-04-15 |
2020-10-22 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
RS64961B1
(sr)
|
2019-04-26 |
2024-01-31 |
Immunogen Inc |
Derivati kamptotecina
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
WO2020236679A1
(en)
*
|
2019-05-17 |
2020-11-26 |
Cytomx Therapeutics, Inc. |
Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
|
|
EP3972982A1
(en)
|
2019-05-20 |
2022-03-30 |
Massachusetts Institute of Technology |
Boronic ester prodrugs and uses thereof
|
|
CA3141130A1
(en)
|
2019-05-31 |
2020-12-03 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
CN113905757B
(zh)
|
2019-06-05 |
2026-01-13 |
中外制药株式会社 |
抗体切割位点结合分子
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
US20220306745A1
(en)
|
2019-06-13 |
2022-09-29 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
WO2020252358A1
(en)
|
2019-06-13 |
2020-12-17 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
WO2020256546A1
(en)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
EP4034171A1
(en)
*
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
US12064507B2
(en)
|
2019-11-19 |
2024-08-20 |
Provectus Pharmatech, Inc. |
Composition and method for oral treatment of leukemia
|
|
WO2021108693A1
(en)
|
2019-11-27 |
2021-06-03 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
|
TWI918599B
(zh)
|
2019-12-31 |
2026-03-21 |
美商希望之城 |
可活化之經掩蔽之抗ctla4結合蛋白
|
|
WO2021141662A1
(en)
|
2020-01-10 |
2021-07-15 |
Massachusetts Institute Of Technology |
Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
|
|
US12662535B2
(en)
|
2020-01-17 |
2026-06-23 |
Immunelogic Therapeutics, Inc. |
Pro-antibody that reduces off-target toxicity
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
TWI920054B
(zh)
*
|
2020-01-23 |
2026-04-01 |
瑞士商天演藥業公司 |
具有Fc突變之異二聚蛋白質
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
MX2022011676A
(es)
*
|
2020-03-23 |
2023-03-08 |
Zymeworks Bc Inc |
Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
|
|
WO2021207657A1
(en)
|
2020-04-09 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
CN111951884B
(zh)
*
|
2020-07-10 |
2022-03-22 |
中南大学 |
蛋白质小分子结合口袋上关键柔性氨基酸的识别方法
|
|
AU2021326469C1
(en)
|
2020-08-11 |
2026-04-30 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
US20220089642A1
(en)
*
|
2020-09-17 |
2022-03-24 |
City Of Hope |
Fc Receptor-ACE2 Conjugates and Use Thereof
|
|
US20230381330A1
(en)
*
|
2020-10-30 |
2023-11-30 |
Avacta Life Sciences Limited |
Enzyme-activated serum extended half-life therapeutic conjugates
|
|
JP2023548310A
(ja)
*
|
2020-10-30 |
2023-11-16 |
アバクタ・ライフ・サイエンシーズ・リミテッド |
Fap活性化血清半減期延長型治療用コンジュゲート
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
EP4259193A4
(en)
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR20230157448A
(ko)
|
2021-03-16 |
2023-11-16 |
싸이톰스 테라퓨틱스, 인크. |
마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
|
|
CA3175637A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Aru NARENDRAN |
Composition and method for oral treatment of leukemia
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
KR20240021943A
(ko)
|
2021-06-18 |
2024-02-19 |
남미 테라퓨틱스, 인크. |
암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
JP2024532409A
(ja)
*
|
2021-08-23 |
2024-09-05 |
コンセプト トゥー メディシン バイオテック カンパニー, リミテッド |
定常ドメインを有する抗体プロドラッグ
|
|
WO2023034825A1
(en)
|
2021-08-30 |
2023-03-09 |
Cytomx Therapeutics, Inc. |
Method for determining protease activity in a biological sample
|
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023060156A2
(en)
|
2021-10-08 |
2023-04-13 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
MX2024004301A
(es)
|
2021-10-08 |
2024-04-26 |
Cytomx Therapeutics Inc |
Construcciones de citocinas activables y metodos combinados.
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
EP4416185A4
(en)
*
|
2021-10-15 |
2025-09-03 |
Harpoon Therapeutics Inc |
CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES
|
|
US20230174995A1
(en)
|
2021-10-15 |
2023-06-08 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex
|
|
PE20241343A1
(es)
|
2021-10-15 |
2024-07-03 |
Cytomx Therapeutics Inc |
Complejo polipeptidico activable
|
|
WO2023100829A1
(ja)
|
2021-11-30 |
2023-06-08 |
第一三共株式会社 |
プロテアーゼ分解性マスク抗体
|
|
WO2023104190A1
(en)
*
|
2021-12-09 |
2023-06-15 |
Vibrant Pharma Limited |
Antibody masks and uses thereof
|
|
AU2023218678A1
(en)
*
|
2022-02-09 |
2024-08-01 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
WO2023161853A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
EP4496816A1
(en)
|
2022-03-23 |
2025-01-29 |
CytomX Therapeutics, Inc. |
Activatable antigen-binding protein constructs and uses of the same
|
|
JP2025512798A
(ja)
*
|
2022-03-25 |
2025-04-22 |
サイトムエックス セラピューティクス,インク. |
活性化可能な二重アンカー型マスク化分子及びその使用方法
|
|
EP4504782A2
(en)
|
2022-04-01 |
2025-02-12 |
CytomX Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
AU2023254206A1
(en)
|
2022-04-13 |
2024-10-17 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
WO2023222580A1
(en)
|
2022-05-16 |
2023-11-23 |
Byondis B.V. |
Novel masked antibodies
|
|
CN119630428A
(zh)
|
2022-07-12 |
2025-03-14 |
西托姆克斯治疗公司 |
Epcam免疫缀合物及其用途
|
|
US20260015425A1
(en)
|
2022-08-01 |
2026-01-15 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
|
AR130077A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Substratos escindibles por proteasas, y métodos de uso de los mismos
|
|
TW202424184A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Cytomx生物製藥公司 |
蛋白酶可切割部分及其使用方法
|
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
JP2025525868A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
WO2024039973A2
(en)
*
|
2022-08-05 |
2024-02-22 |
Staidson Biopharma Inc. |
Masking polypeptide, activatable novel prodrugs and methods of use thereof
|
|
CN117672346B
(zh)
*
|
2022-08-23 |
2026-06-23 |
深圳太力生物技术有限责任公司 |
一种基于对接阻断模型的靶向前药掩蔽评价方法与系统
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024150174A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
WO2024173795A1
(en)
*
|
2023-02-17 |
2024-08-22 |
California Institute Of Technology |
Activatable drug conjugates and therapeutic applications thereof
|
|
EP4694934A1
(en)
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
CN120958015A
(zh)
|
2023-04-12 |
2025-11-14 |
西托姆克斯治疗公司 |
掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
|
|
KR20260056204A
(ko)
|
2023-08-14 |
2026-04-24 |
보로 테라퓨틱스, 인코포레이티드 |
표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
TW202540163A
(zh)
*
|
2024-01-11 |
2025-10-16 |
日商第一三共股份有限公司 |
利用環境應答性胜肽的蛋白質之製造方法
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|
|
WO2026083296A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
|
|
WO2026083295A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
|
|
WO2026102136A1
(en)
*
|
2024-11-07 |
2026-05-15 |
Glyconex Inc. |
Anti-lewis y antibody and pro-antibody thereof
|
|
WO2026112598A1
(en)
|
2024-11-25 |
2026-05-28 |
Modernatx, Inc. |
Messenger rna encoding masked proteins and compositions and uses thereof
|
|
WO2026117686A1
(en)
|
2024-11-27 |
2026-06-04 |
Nammi Therapeutics, Inc. |
FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
|
|
WO2026161794A1
(en)
|
2025-01-27 |
2026-07-30 |
Cytomx Therapeutics, Inc. |
Epcam immunoconjugates and therapeutic uses thereof
|